These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 2536911

  • 1. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study.
    Curry SL, Blessing JA, DiSaia PJ, Soper JT, Twiggs LB.
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):357-62. PubMed ID: 2536911
    [Abstract] [Full Text] [Related]

  • 2. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
    Soper JT, Evans AC, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB.
    Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
    [Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
    Deng L, Zhang J, Wu T, Lawrie TA.
    Cochrane Database Syst Rev; 2013 Jan 31; 2013(1):CD005196. PubMed ID: 23440800
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy with the modified Bagshawe protocol for poor prognosis metastatic trophoblastic disease.
    Weed JC, Barnard DE, Currie JL, Clayton LA, Hammond CB.
    Obstet Gynecol; 1982 Mar 31; 59(3):377-80. PubMed ID: 6176924
    [Abstract] [Full Text] [Related]

  • 5. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
    Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR.
    Obstet Gynecol; 1992 Nov 31; 80(5):817-20. PubMed ID: 1328977
    [Abstract] [Full Text] [Related]

  • 6. "Poor prognosis" metastatic gestational trophoblastic disease: the prognostic significance of the scoring system in predicting chemotherapy failures.
    Mortakis AE, Braga CA.
    Obstet Gynecol; 1990 Aug 31; 76(2):272-7. PubMed ID: 2164651
    [Abstract] [Full Text] [Related]

  • 7. Modified Bagshawe's regimen in high-risk gestational trophoblastic disease.
    Wong LC, Choo YC, Ma HK.
    Gynecol Oncol; 1986 Jan 31; 23(1):87-93. PubMed ID: 3002917
    [Abstract] [Full Text] [Related]

  • 8. Gestational trophoblastic disease.
    Hammond CB, Olt GJ.
    Curr Ther Endocrinol Metab; 1994 Jan 31; 5():567-70. PubMed ID: 7704794
    [No Abstract] [Full Text] [Related]

  • 9. Liver metastases of gestational trophoblastic tumor.
    Bakri YN, Subhi J, Amer M, Ezzat A, Sinner W, Tweijry A, Jabbar FA.
    Gynecol Oncol; 1993 Jan 31; 48(1):110-3. PubMed ID: 8380786
    [Abstract] [Full Text] [Related]

  • 10. Management of high-risk gestational trophoblastic disease.
    Surwit EA.
    J Reprod Med; 1987 Sep 31; 32(9):657-62. PubMed ID: 2822919
    [Abstract] [Full Text] [Related]

  • 11. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
    Surwit EA, Childers JM.
    J Reprod Med; 1991 Jan 31; 36(1):45-8. PubMed ID: 1848900
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD, Wolff SN, Stein RS, Greer JP, Cousar JB, Greco FA.
    Cancer Treat Rep; 1986 Aug 31; 70(8):953-8. PubMed ID: 3015406
    [Abstract] [Full Text] [Related]

  • 14. Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy.
    Lurain JR, Brewer JI.
    Obstet Gynecol; 1985 Jun 31; 65(6):830-6. PubMed ID: 2987766
    [Abstract] [Full Text] [Related]

  • 15. Poor-prognosis gestational trophoblastic disease: an update.
    Surwit EA, Alberts DS, Christian CD, Graham VE.
    Obstet Gynecol; 1984 Jul 31; 64(1):21-6. PubMed ID: 6204257
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
    Kohorn EI.
    Gynecol Oncol; 1993 Sep 31; 50(3):300-4. PubMed ID: 8406191
    [Abstract] [Full Text] [Related]

  • 18. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens.
    Abrão RA, de Andrade JM, Tiezzi DG, Marana HR, Candido dos Reis FJ, Clagnan WS.
    Gynecol Oncol; 2008 Jan 31; 108(1):149-53. PubMed ID: 17931696
    [Abstract] [Full Text] [Related]

  • 19. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease.
    Hartenbach EM, Saltzman AK, Carter JR, Twiggs LB.
    Gynecol Oncol; 1995 Jan 31; 56(1):105-8. PubMed ID: 7529741
    [Abstract] [Full Text] [Related]

  • 20. Development of single-agent chemotherapy regimens for gestational trophoblastic disease.
    Homesley HD.
    J Reprod Med; 1994 Mar 31; 39(3):185-92. PubMed ID: 7518517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.